

Resource Summary Report

Generated by [nidm-terms](#) on Aug 18, 2026

Multiclone CD4 FITC 100 Tests RUO/GMP

RRID:AB_400297

Type: Antibody

Proper Citation

BD Biosciences Cat# 347413, RRID:AB_400297

Antibody Information

URL: http://antibodyregistry.org/AB_400297

Proper Citation: BD Biosciences Cat# 347413, RRID:AB_400297

Target Antigen: CD4

Host Organism: mouse

Clonality: monoclonal

Comments: Applications: Flow cytometry

Antibody Name: Multiclone CD4 FITC 100 Tests RUO/GMP

Description: This monoclonal targets CD4

Target Organism: human

Antibody ID: AB_400297

Vendor: BD Biosciences

Catalog Number: 347413

Record Creation Time: 20250820T055513+0000

Record Last Update: 20250820T224907+0000

Ratings and Alerts

No rating or validation information has been found for Multiclone CD4 FITC 100 Tests RUO/GMP.

No alerts have been found for Multiclone CD4 FITC 100 Tests RUO/GMP.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 6 mentions in open access literature.

Listed below are recent publications. The full list is available at [nidm-terms](#) .

Neehus AL, et al. (2024) Human inherited CCR2 deficiency underlies progressive polycystic lung disease. *Cell*, 187(2), 390.

Bergaggio E, et al. (2023) ALK inhibitors increase ALK expression and sensitize neuroblastoma cells to ALK.CAR-T cells. *Cancer cell*, 41(12), 2100.

Frentzas S, et al. (2023) A phase 1a/1b first-in-human study (COMPASSION-01) evaluating cadonilimab in patients with advanced solid tumors. *Cell reports. Medicine*, 4(11), 101242.

Vyasamneni R, et al. (2023) A universal MHCII technology platform to characterize antigen-specific CD4+ T cells. *Cell reports methods*, 3(1), 100388.

de Silva TI, et al. (2021) The impact of viral mutations on recognition by SARS-CoV-2 specific T cells. *iScience*, 24(11), 103353.

Ott PA, et al. (2020) A Phase Ib Trial of Personalized Neoantigen Therapy Plus Anti-PD-1 in Patients with Advanced Melanoma, Non-small Cell Lung Cancer, or Bladder Cancer. *Cell*, 183(2), 347.